Clinicopathological features and five-year survival of invasive non- metastatic breast cancer patients surgically treated in a single breast unit in Jordan in 2013

Abstract EN

Background : breast cancer is still the most common cancer in females worldwide.

in 2013, the number of female breast cancer cases in Jordan was 1040 (36.5% of all female cancers)1.

studying survival and clinico-pathological features will provide an objective assessment about tumour biology in our region and specific treatment outcomes.

Objective : to assess the five-year survival of breast cancer patients who were treated at our breast unit, to evaluate clinicopathlogical features and correlate them with molecular subtypes.

materials and methods : a retrospective study that revised the histopathology reports of 129 breast cancer patients surgically treated at al-Hussein hospital from January 2013 until January 2014.

the patients were followed up till 2019 to assess their 5 year survival, clinicopathological features and molecular subtypes.

Results : the most common age group was 40–60 years (51.16%).

eighty six (66.67%) patients had axillary ln involvement.

most of the tumours were reported to be between 2 and 5 cm (t2) in 82 (63.57%) patients.

one hundred and fifteen (89.15%) patients had invasive ductal carcinoma (idc) nonspecific type.

grade 3 tumours were reported in 64 (49.61%) patients.

the tumours in 105 (81.40%) patients were er positive, those in 94 (72.87%) patients were pr positive and those in 96 (74.42%) patients were her2 receptor negative.

luminal a subtype was observed in 86 (66.6%) patients, followed by luminal b subtype in 21 (16.28%) then her2 enriched subtype in 12 (9.30%) and least in triple negative subtype in 10 (7.75%) patients.

there were nine (6.98%) patients who had stage 1, 58(44.96%) patients had stage 2 and 62 (46.06%) patients who had stage 3.

the five year survival according to stage was 100%, 87.93%, 69.35% for stages 1, 2 and 3 respectively.

conclusion : approximately half of the patients presented in the middle age group with relatively large tumour sizes and involved lymph nodes.

however, the majority of patients had a favourable molecular subtype (luminal a) accounting for why the 5-year survival for stage 3 was around 70%, which is relatively good and is comparable to worldwide results.

there was also a significant relationship (p = 0.022) between molecular subtypes and age groups used in the study warranting larger scale studies.